SynthesisFrontiers in oncology2021
Predictive Performance of Serum S100B
Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- Review
- The Diagnostic Promise of Serum S100B Protein in Pregnancy-Related Hypertension: A Narrative Review.Health science reports · 2026Article
- Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations.International journal of molecular sciences · 2026Review
- Serum Arginase-1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness.Oncoimmunology · 2025Article
- Identification of biomarkers related to the progression of cutaneous melanoma and construction of survival prognosis model.Discover oncology · 2025Article
- Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.International journal of dermatology · 2025Article
- Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy.Dermatopathology (Basel, Switzerland) · 2025Review
- The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals.Cell reports. Medicine · 2025Article
- Pigmented skin lesions with atypical histopathology indicating a diagnosis of multiple metastases of melanoma: A case report.Oncology letters · 2025Article
- Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.BJC reports · 2025Article
- Article
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.Cancers · 2024Review
- Melanoma in a Colombian population: a survival study.Melanoma management · 2024Article
- Changes in S100 calcium-binding protein β (S100β) and cognitive function from pre- to post-chemotherapy among women with breast cancer.Brain, behavior, & immunity - health · 2024Article
- Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.Cancer medicine · 2024Article
- Article
- Combining Biomarkers for the Diagnosis of Metastatic Melanoma.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, no consensus on the use of blood tests for monitoring disease recurrence in patients with resected melanoma exists. The only meta-analysis conducted in 2008 found that elevated serum S100B levels were associated with significantly worse survival in melanoma patients. Serum LDH is an established prognostic factor in patients with advanced melanoma.
objectiveTo compare the discriminative and prognostic ability of serum S100B with that of serum LDH in patients with melanoma.
methodsThis systematic review and meta-analysis were reported in accordance with the PRISMA Statement. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138).
resultsA quantitative analysis of data from 6 eligible studies included 1,033 patients with cutaneous melanoma. The discriminative ability of serum S100B at identifying disease relapse [pooled Area Under the ROC (AUROC) 78.64 (95% CI 70.28; 87.01)] was significantly greater than the discriminative ability of serum LDH [AUROC 64.41 (95% CI 56.05; 7278)] (p=0.013). Ten eligible studies with 1,987 patients were included in the risk of death analysis. The prognostic performance of serum S100B [pooled estimate of adjusted hazard ratio (HR) 1.78 (95% CI 1.38; 2.29)] was independent but not superior to that of serum LDH [HR 1.60 (95% CI 1.36; 2.29)]. LIMITATIONS: A relatively small number of articles were eligible and there was considerable heterogeneity across the included studies.
conclusionsSerum biomarkers may provide relevant information on melanoma patient status and should be further researched. Serum S100B is a valid marker for diagnosis of melanoma recurrence. SYSTEMATIC REVIEW REGISTRATION: The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.